trovafloxacin has been researched along with sparfloxacin in 41 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (53.66) | 18.2507 |
| 2000's | 16 (39.02) | 29.6817 |
| 2010's | 3 (7.32) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Appelbaum, PC; Bhawsar, SB; Bozdogan, B; de Souza, NJ; Desai, VN; Deshpande, PK; Gupte, SV; Hooper, DC; Jacobs, MR; Jha, R; Khorakiwala, HF; Patel, MV; Shetty, N; Shukla, MC; Strahilevitz, J; Yeole, RD | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Azéma, J; Dewelle, J; Guidetti, B; Kiss, R; Korolyov, A; Le Calve, B; Malet-Martino, M; Martino, R; Mijatovic, T; Vaysse, J | 1 |
| Avdeef, A; Sun, N; Tam, KY; Tsinman, O | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Cooper, B; Freeman, C; Mazens-Sullivan, M; Nightingale, C; Quintiliani, R; Robinson, A | 1 |
| Anderson, MR; Brighty, KE; Castaldi, MJ; Gootz, TD; Haskell, SL; McGuirk, PR; Schmieder, BJ; Sutcliffe, JA | 1 |
| Chin, NX; Neu, HC | 1 |
| Appelbaum, PC; Jacobs, MR; Visalli, MA | 1 |
| Cartwright, FD; Kenny, GE | 1 |
| Aoun, M; Crokaert, F; Duchateau, V; Grenier, P; Klastersky, J; Vandermies, A | 1 |
| Hecht, DW; Wexler, HM | 1 |
| Goldstein, EJ | 1 |
| Andrews, JM; Boswell, F; Brenwald, NP; Wise, R | 1 |
| Dvorak, T; Ho, DH; LeBlanc, B; Rolston, KV; Streeter, H | 1 |
| Appelbaum, PC; Jacobs, MR; Spangler, SK | 1 |
| Hoogkamp-Korstanje, JA | 1 |
| Brookings, E; Gray, B; Nix, S; Robinson, A; Swiatlo, E; Waites, K | 1 |
| Hoban, DJ; Karlowsky, JA; Zhanel, GG | 1 |
| Giamarellos-Bourboulis, EJ; Giamarellou, H; Grecka, P; Sambatakou, H | 1 |
| Biedenbach, DJ; Croco, MA; Doern, GV; Jones, RN; Pfaller, MA | 1 |
| Beach, ML; Doern, GV; Jones, RN; Pfaller, MA | 1 |
| Biavasco, F; Mingoia, M; Montanari, MP; Prenna, M; Ripa, S; Varaldo, PE | 1 |
| Heisig, P; Jones, ME; Klootwijk, M; Schmitz, FJ; Verhoef, J; Visser, MR | 1 |
| Appelbaum, PC; Hoellman, DB; Jacobs, MR; Lin, G | 1 |
| Gootz, TD; Haskell, SL; Kaczmarek, FS; Maurice, AE; Zaniewski, RP | 1 |
| Beyer, R; Cianciotto, NP; Noskin, GA; Pestova, E; Peterson, LR | 1 |
| Hooper, DC | 2 |
| Hershberger, E; Rybak, MJ | 1 |
| Beyer, R; Millichap, JJ; Noskin, GA; Pestova, E; Peterson, LR; Stosor, V | 1 |
| Amsterdam, D; Hardy, D; Mandell, LA; Rotstein, C | 1 |
| Anderson, VE; Gootz, TD; Kaczmarek, FS; Osheroff, N; Zaniewski, RP | 1 |
| King, DE; Lilley, SH; Malone, R | 1 |
| Bebear, C; Bebear, CM; Charron, A; Gruson, D; Lefrancois, M; Renaudin, H | 1 |
| Kanayama, A; Kobayashi, I; Mochida, O; Naito, S; Saika, T; Tanaka, M; Tunoe, H | 1 |
| Gootz, TD | 1 |
| Hovde, LB; Peterson, ML; Ross, GH; Rotschafer, JC; Wright, DH | 1 |
| Yagawa, K | 1 |
5 review(s) available for trovafloxacin and sparfloxacin
| Article | Year |
|---|---|
Quinolone antibiotics.
Topics: | 2019 |
Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolones; Safety; Syndrome | 1996 |
New uses for new and old quinolones and the challenge of resistance.
Topics: Anti-Infective Agents; Bacterial Infections; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Piperazines; Respiratory Tract Infections; Sensitivity and Specificity; Sexually Transmitted Diseases; Urinary Tract Infections | 2000 |
The fluoroquinolones after ciprofloxacin and ofloxacin.
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Naphthyridines; Ofloxacin; Piperazines; Respiratory Tract Infections; Sexually Transmitted Diseases, Bacterial; Skin Diseases, Bacterial; Urinary Tract Infections | 2000 |
Latest industry information on the safety profile of levofloxacin in Japan.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Infective Agents; Central Nervous System; Chemical and Drug Induced Liver Injury; Dermatitis, Phototoxic; Drug Industry; Fluoroquinolones; Heart Diseases; Humans; Japan; Levofloxacin; Naphthyridines; Ofloxacin; Seizures; Substance Withdrawal Syndrome | 2001 |
36 other study(ies) available for trovafloxacin and sparfloxacin
| Article | Year |
|---|---|
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Dogs; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Mutation; Prodrugs; Quinolizines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Vancomycin Resistance | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum Tolerated Dose; Mice; Neoplasms; Piperazine; Piperazines | 2009 |
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Topics: Caco-2 Cells; Cell Membrane Permeability; Humans; Hydrogen-Ion Concentration; Membranes, Artificial; Molecular Structure; Pharmaceutical Preparations | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Depsipeptides; Drug Resistance, Microbial; Enterococcus; Fluoroquinolones; Fusidic Acid; Microbial Sensitivity Tests; Minocycline; Naphthyridines; Novobiocin; Peptides, Cyclic; Quinolones; Teicoplanin; Vancomycin; Virginiamycin | 1995 |
In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA Topoisomerases, Type II; DNA, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Naphthyridines; Quinolones | 1994 |
In vitro activity of the new fluoroquinolone CP-99,219.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Naphthyridines; Quinolones | 1994 |
Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology.
Topics: Anti-Infective Agents; Cefuroxime; Ciprofloxacin; Fluoroquinolones; Microbial Sensitivity Tests; Naphthyridines; Penicillin Resistance; Quinolones; Streptococcus pneumoniae | 1996 |
Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).
Topics: Anti-Infective Agents; Fluoroquinolones; Microbial Sensitivity Tests; Mycoplasma; Mycoplasma pneumoniae; Naphthyridines; Ofloxacin; Quinolones; Ureaplasma urealyticum | 1996 |
In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens.
Topics: Anti-Infective Agents; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moraxella catarrhalis; Naphthyridines; Quinolones; Respiratory Tract Infections; Streptococcus pneumoniae | 1996 |
In vitro susceptibility of anaerobes to quinolones in the United States.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Culture Media; Drug Resistance, Microbial; Evaluation Studies as Topic; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Piperazines; Quinolones; United States | 1996 |
The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteroides fragilis; Chlamydia; Ciprofloxacin; Clarithromycin; Doxycycline; Enterobacter; Erythromycin; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Haemophilus influenzae; Microbial Sensitivity Tests; Naphthyridines; Piperazines; Pseudomonas aeruginosa; Quinolones; Streptococcus pneumoniae | 1997 |
In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Neoplasms; Norfloxacin; Ofloxacin; Quinolones | 1997 |
Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.
Topics: Anti-Infective Agents; Bacteroides; Bacteroides fragilis; Cefoxitin; Ciprofloxacin; Clostridium perfringens; Fluoroquinolones; Fusobacterium; Gram-Negative Anaerobic Bacteria; Metronidazole; Microbial Sensitivity Tests; Naphthyridines; Penicillanic Acid; Peptostreptococcus; Piperacillin; Prevotella melaninogenica; Quinolones; Tazobactam | 1997 |
In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Pefloxacin; Quinolones; Respiratory Tract Infections | 1997 |
Comparative in vitro activities of four new fluoroquinolones against Streptococcus pneumoniae determined by Etest.
Topics: Anti-Infective Agents; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Streptococcus pneumoniae | 1998 |
In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Drug Resistance, Microbial; Enterococcus; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Vancomycin | 1998 |
In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Enterococcus faecalis; Enterococcus faecium; Fluoroquinolones; Gentamicins; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Virginiamycin | 1998 |
In-vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp.
Topics: Anti-Infective Agents; Fluoroquinolones; Gatifloxacin; Humans; Legionella; Legionella pneumophila; Legionellosis; Microbial Sensitivity Tests; Naphthyridines; Quinolones | 1998 |
Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America.
Topics: Anti-Infective Agents; Antitubercular Agents; Bacteriological Techniques; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Naphthyridines; North America; Quinolones; South America | 1998 |
Antistaphylococcal and antistreptococcal killing kinetics of ciprofloxacin, ofloxacin, sparfloxacin, and trovafloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pneumoniae; Streptococcus pyogenes | 1998 |
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-re
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus; Vancomycin; Virginiamycin | 1999 |
Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
Topics: Amoxicillin; Anti-Infective Agents; Ceftriaxone; Cefuroxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Streptococcus pneumoniae | 1999 |
Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Topics: Adrenergic Uptake Inhibitors; Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; DNA, Bacterial; DNA, Superhelical; Drug Interactions; Drug Resistance, Microbial; Enzyme Inhibitors; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Naphthyridines; Ofloxacin; Reserpine; Staphylococcus aureus; Topoisomerase II Inhibitors | 1999 |
Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
Topics: Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; DNA, Bacterial; Drug Resistance, Microbial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Naphthyridines; Ofloxacin; Phenotype; Streptococcus pneumoniae; Transformation, Bacterial | 1999 |
Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Topics: Anti-Infective Agents; Blood Coagulation; Ciprofloxacin; Fibrin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Pneumococcal Infections; Streptococcus pneumoniae | 2000 |
A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Microbial; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Quinolines; Reserpine; Staphylococcus aureus; Streptococcus pneumoniae | 2000 |
Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Fluoroquinolones; Gemifloxacin; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines | 2000 |
Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
Topics: Anti-Infective Agents; Catalysis; Ciprofloxacin; DNA; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Levofloxacin; Naphthyridines; Ofloxacin; Staphylococcus aureus; Topoisomerase II Inhibitors | 2000 |
New classification and update on the quinolone antibiotics.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Humans; Naphthyridines | 2000 |
In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Doxycycline; Drug Resistance, Microbial; Erythromycin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mycoplasma hominis; Naphthyridines; Ofloxacin; Ureaplasma urealyticum | 2000 |
Antimicrobial activity of gemifloxacin (SB-265805), a newer fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae, including fluoroquinolone-resistant isolates.
Topics: Amoxicillin; Anti-Infective Agents; Ciprofloxacin; Clavulanic Acid; Drug Resistance, Microbial; Fluoroquinolones; Gemifloxacin; Gonorrhea; Humans; Levofloxacin; Naphthyridines; Neisseria gonorrhoeae; Norfloxacin; Ofloxacin | 2000 |
Bactericidal assays for fluoroquinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA Topoisomerases, Type II; DNA, Superhelical; Escherichia coli; Fluoroquinolones; Kinetics; Microbial Sensitivity Tests; Naphthyridines; Nephelometry and Turbidimetry; Plasmids; Quality Control; Topoisomerase II Inhibitors | 2001 |
Fluoroquinolone resistance in anaerobic bacteria following exposure to levofloxacin, trovafloxacin, and sparfloxacin in an in vitro pharmacodynamic model.
Topics: Anti-Infective Agents; Bacteroides; Drug Resistance, Microbial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Time Factors | 2001 |